Market Cap | 1.17B | P/E | - | EPS this Y | 4.90% | Ern Qtrly Grth | - |
Income | -163.43M | Forward P/E | -42.22 | EPS next Y | -53.80% | 50D Avg Chg | 2.00% |
Sales | 290.7M | PEG | 1.03 | EPS past 5Y | 21.67% | 200D Avg Chg | 13.00% |
Dividend | N/A | Price/Book | 0.92 | EPS next 5Y | -52.25% | 52W High Chg | -40.00% |
Recommedations | 2.70 | Quick Ratio | 4.96 | Shares Outstanding | 30.30M | 52W Low Chg | 39.00% |
Insider Own | 32.01% | ROA | -3.32% | Shares Float | 20.13M | Beta | 1.50 |
Inst Own | 51.79% | ROE | -14.28% | Shares Shorted/Prior | 723.21K/699.33K | Price | 39.26 |
Gross Margin | 39.10% | Profit Margin | -56.22% | Avg. Volume | 205,009 | Target Price | 27.67 |
Oper. Margin | -26.62% | Earnings Date | Nov 1 | Volume | 194,782 | Change | 1.11% |
Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.
Piper Sandler | Neutral | Mar 6, 24 |
UBS | Neutral | Dec 7, 23 |
Piper Sandler | Neutral | Oct 16, 23 |
Credit Suisse | Outperform | Mar 2, 23 |
Piper Sandler | Neutral | Dec 8, 22 |
Raymond James | Outperform | Nov 18, 22 |
Credit Suisse | Outperform | Nov 14, 22 |
Piper Sandler | Overweight | Nov 14, 22 |
Credit Suisse | Outperform | Aug 25, 22 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Xie Jian | President and COO President and COO | Dec 11 | Sell | 26.5 | 22,000 | 583,000 | 363,124 | 12/13/23 |
Xie Jian | President and COO President and COO | Dec 04 | Sell | 27.5732 | 1,779 | 49,053 | 385,124 | 12/06/23 |
Kim Paul | CFO and Treasurer CFO and Treasurer | Dec 04 | Sell | 27.5732 | 1,437 | 39,623 | 200,460 | 12/06/23 |
Gao Hanlin | Chief Scientific Off.. Chief Scientific Officer | Dec 04 | Sell | 27.5732 | 1,437 | 39,623 | 905,882 | 12/06/23 |
Xie Jian | President and COO President and COO | Nov 16 | Sell | 27.2511 | 1,617 | 44,065 | 386,903 | 11/20/23 |
Kim Paul | CFO and Treasurer CFO and Treasurer | Nov 16 | Sell | 27.2511 | 1,307 | 35,617 | 201,897 | 11/20/23 |
Xie Jian | President and COO President and COO | Sep 07 | Sell | 31.4079 | 1,492 | 46,861 | 416,022 | 09/11/23 |
Kim Paul | CFO and Treasurer CFO and Treasurer | Sep 07 | Sell | 31.4079 | 1,492 | 46,861 | 214,061 | 09/11/23 |
Kim Paul | CFO and Treasurer CFO and Treasurer | Aug 28 | Sell | 33.6243 | 10,299 | 346,297 | 215,553 | 08/30/23 |
Xie Jian | President and COO President and COO | Jun 02 | Sell | 40.2961 | 1,433 | 57,744 | 425,794 | 06/06/23 |
Kim Paul | CFO and Treasurer CFO and Treasurer | Jun 02 | Sell | 40.2961 | 1,403 | 56,535 | 228,890 | 06/06/23 |
Gao Hanlin | Chief Scientific Off.. Chief Scientific Officer | Jun 02 | Sell | 40.2961 | 1,000 | 40,296 | 914,391 | 06/06/23 |
Xie Jian | President and COO President and COO | Nov 30 | Sell | 34.3932 | 685 | 23,559 | 430,074 | 12/02/22 |
KIM PAUL | CFO and Treasurer CFO and Treasurer | Sep 06 | Sell | 41.3942 | 662 | 27,403 | 149,507 | 09/08/22 |
Xie Jian | President and COO President and COO | Aug 30 | Sell | 44.183 | 675 | 29,824 | 309,729 | 09/01/22 |
Xie Jian | President and COO President and COO | Aug 17 | Sell | 48.8945 | 1,414 | 69,137 | 310,404 | 08/19/22 |
KIM PAUL | CFO and Treasurer CFO and Treasurer | Aug 17 | Sell | 48.8945 | 1,945 | 95,100 | 150,169 | 08/19/22 |
Gao Hanlin | Chief Scientific Off.. Chief Scientific Officer | Aug 17 | Sell | 48.8945 | 370 | 18,091 | 855,280 | 08/19/22 |
KIM PAUL | CFO and Treasurer CFO and Treasurer | Jun 02 | Sell | 55.102 | 415 | 22,867 | 153,162 | 06/06/22 |
KIM PAUL | CFO and Treasurer CFO and Treasurer | Mar 03 | Sell | 56.3081 | 454 | 25,564 | 155,574 | 03/04/22 |
KIM PAUL | CFO and Treasurer CFO and Treasurer | Nov 16 | Sell | 96.16 | 2,169 | 208,571 | 131,826 | 11/18/21 |
KIM PAUL | CFO and Treasurer CFO and Treasurer | Jun 04 | Sell | 72.8 | 1,250 | 91,000 | 142,188 | 06/04/21 |
KIM PAUL | CFO and Treasurer CFO and Treasurer | May 27 | Sell | 72.92 | 28,358 | 2,067,865 | 143,438 | 05/27/21 |
Xie Jian | Chief Operating Offi.. Chief Operating Officer | May 20 | Sell | 72.6 | 1,931 | 140,191 | 340,041 | 05/20/21 |